| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrine Unit (P.L., S.Be., S.Ba., I.C., M.S., A.P.) and Clinical Biochemistry Unit (S.G.), Department of Clinical Physiopathology, Center for Research, Transfer, and High Education on Chronic, Inflammatory, Degenerative, and Neoplastic Disorders (DENOthe), University of Florence, 50139 Florence, Italy; Neurosurgery Unit, Careggi Hospital (F.A.), 50139 Florence, Italy; and Institute of Endocrine Sciences, University of Milan, Ospedale Maggiore IRCCS (E.F., A.L., G.M., A.S.), 20122 Milan, Italy
Address all correspondence and requests for reprints to: Prof. Alessandro Peri, Endocrine Unit, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy. E-mail: a.peri{at}dfc.unifi.it.
Context: Seladin-1 (from selective Alzheimers disease indicator-1) is a recently discovered gene that has been found to be down-regulated in brain regions affected by Alzheimers disease. Seladin-1 effectively protects neurons against ß-amyloid-mediated toxicity and prevents apoptosis via inhibition of the activation of caspase-3, a key mediator of the apoptotic cascade. Although seladin-1 is expressed in the pituitary gland, no study addressed the expression or the function of this gene in pituitary adenomas.
Objective: The aim of the present study was to determine the expression level of the seladin-1 gene in pituitary tumors, i.e. GH-secreting and nonfunctioning pituitary adenomas (NFPA), and to determine whether differential expression might be associated with different somatostatin (sst)-induced apoptosis.
Results: We found by quantitative real-time RT-PCR that the expression level of seladin-1 was significantly higher in NFPA (n = 21) than in GH-secreting adenomas (n = 30; mean ± SE, 25.69 ± 6.39 vs. 8.02 ± 2.68 pg/µg total RNA; P = 0.006). Although the amount of activated caspase-3 did not differ between the two groups of tumors, in primary cell cultures, octreotide was able to increase apoptosis, evaluated by the level of cleaved cytokeratin 18 and the presence of apoptotic nuclei, in GH-secreting adenomas, but not in NFPA. This different response was not attributable to differences in the amount of transcript of sst receptors 2 and 5, which was similar in the two groups of tumors.
Conclusions: Our results suggest that differential seladin-1 expression in pituitary adenomas may be associated with a different apoptotic response to sst analogs.
This article has been cited by other articles:
![]() |
J. Acunzo, S. Thirion, C. Roche, A. Saveanu, G. Gunz, A. L. Germanetti, B. Couderc, R. Cohen, D. Figarella-Branger, H. Dufour, et al. Somatostatin Receptor sst2 Decreases Cell Viability and Hormonal Hypersecretion and Reverses Octreotide Resistance of Human Pituitary Adenomas Cancer Res., December 15, 2008; 68(24): 10163 - 10170. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Peri and M. Serio Neuroprotective effects of the Alzheimer's disease-related gene seladin-1 J. Mol. Endocrinol., November 1, 2008; 41(5): 251 - 261. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Luciani, C. Deledda, F. Rosati, S. Benvenuti, I. Cellai, F. Dichiara, M. Morello, G. B. Vannelli, G. Danza, M. Serio, et al. Seladin-1 Is a Fundamental Mediator of the Neuroprotective Effects of Estrogen in Human Neuroblast Long-Term Cell Cultures Endocrinology, September 1, 2008; 149(9): 4256 - 4266. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kuehnle, A. Crameri, R. E. Kalin, P. Luciani, S. Benvenuti, A. Peri, F. Ratti, M. Rodolfo, L. Kulic, F. L. Heppner, et al. Prosurvival Effect of DHCR24/Seladin-1 in Acute and Chronic Responses to Oxidative Stress Mol. Cell. Biol., January 15, 2008; 28(2): 539 - 550. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Zatelli, M. R. Ambrosio, M. Bondanelli, and E. C d. Uberti Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S29 - S35. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Battista, C. Roberge, M. Otis, and N. Gallo-Payet Seladin-1 expression in rat adrenal gland: effect of adrenocorticotropic hormone treatment J. Endocrinol., January 1, 2007; 192(1): 53 - 66. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Ferrante, C Pellegrini, S Bondioni, E Peverelli, M Locatelli, P Gelmini, P Luciani, A Peri, G Mantovani, S Bosari, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr. Relat. Cancer, September 1, 2006; 13(3): 955 - 962. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |